Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

This phase 3 SUNMO trial evaluated the combination of mosunetuzumab and polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with refractory or relapsed large B-cell lymphoma (LBCL) who are ineligible for autologous stem cell transplant.

Among 208 randomized patients, Mosun-Pola demonstrated:

• Significantly longer median progression-free survival: 11.5 vs 3.8 months (HR 0.41; P<0.0001)
• Higher overall response rate: 70% vs 40% (P<0.0001)
• Complete response rates: 51% vs 24%

Mosun-Pola was associated with low rates (<5%) of grade ≥2 cytokine release syndrome and showed improved patient-reported outcomes, indicating a manageable safety profile.

This fixed-duration outpatient regimen offers a superior efficacy option for this difficult-to-treat population.